LOGGIC Core
Research type
Research Study
Full title
Low Grade Glioma in Children (LOGGIC) Core BioClinical Data Bank
IRAS ID
358899
Contact name
Darren Hargrave
Contact email
Sponsor organisation
University of Birmingham
Duration of Study in the UK
4 years, 11 months, 31 days
Research summary
Tumours result from changes in the cells within the body, which cause diseased cells to grow and divide uncontrollably, displacing healthy cells. Researchers are trying to learn more about the specific genetic changes in Low Grade Gliomas (LGGs). LGGs are slow growing brain tumours that start in glial cells, which normally support the brain and spinal cord.
Many LGGs can be treated with surgery alone, but some require additional treatment. This is because the tumour has grown, the patient has symptoms that are continuing because of the tumour, or it was not possible to completely remove the tumour during surgery. With the help of genetic information, it may be possible to develop new treatment strategies for future patients and to individualise treatment, for example by estimating whether a tumour has a certain change and therefore could respond to a particular treatment.
LOGGIC Core is a European study for children and young people with LGG. When a patient with LGG has surgery, this study will seek to find out as much about the tumour as possible. To do this, we will carry out laboratory tests on samples, some of which will identify if there are genetic mutations. We will also look at patients' blood to identify which genetic mutations are only seen in the tumour, and those which are part of that individual's overall 'make up' (in all cells of their body). Information gathered from the study will feed into both academic and industry funded European and international clinical trials to help understand patient outcomes and prognosis. The study will take place in NHS hospitals. Tumour samples from routine surgeries at diagnosis and relapse, and blood samples collected at diagnosis and relapse, will be used for the study. Where patients consent, leftover cerebrospinal fluid (CSF) from routine procedures will also be analysed.REC name
South Central - Berkshire Research Ethics Committee
REC reference
26/SC/0124
Date of REC Opinion
24 Apr 2026
REC opinion
Favourable Opinion